Abbott Laboratories vs Superluminal Medicines

Side-by-side comparison of AI visibility scores, market position, and capabilities

Superluminal Medicines leads in AI visibility (86 vs 81)
Abbott Laboratories logo

Abbott Laboratories

LeaderHealthcare

General

Diversified healthcare company with $20-22B revenue; FreeStyle Libre CGM, cardiovascular devices, and diagnostics across medical devices, nutrition, and pharma.

AI VisibilityBeta
Overall Score
A81
Category Rank
#78 of 1158
AI Consensus
58%
Trend
stable
Per Platform
ChatGPT
85
Perplexity
91
Gemini
75

About

Abbott Laboratories is a diversified global healthcare company operating across diagnostics, medical devices, nutritional products, and established pharmaceuticals in over 160 countries. Founded in 1888 by Dr. Wallace Calvin Abbott in Chicago, Illinois and listed on the NYSE, Abbott generates approximately $20-22 billion in annual revenue and employs over 100,000 people globally. The company's portfolio spans four major segments: Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals.

Full profile
Superluminal Medicines logo

Superluminal Medicines

LeaderHealthcare

General

Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.

AI VisibilityBeta
Overall Score
A86
Category Rank
#85 of 1158
AI Consensus
59%
Trend
stable
Per Platform
ChatGPT
83
Perplexity
80
Gemini
93

About

Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.

Full profile

AI Visibility Head-to-Head

81
Overall Score
86
#78
Category Rank
#85
58
AI Consensus
59
stable
Trend
stable
85
ChatGPT
83
91
Perplexity
80
75
Gemini
93
91
Claude
83
80
Grok
95

Key Details

Category
General
General
Tier
Leader
Leader
Entity Type
company
brand

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.